Markets

The G1A™ test has the potential to benefit ALL diabetics.

FUTURE MARKETS

Type 2 Diabetics
Integrate the G1A™ monthly test for glycation into corporate and community wellness and consultation programs.

• Accounts for approximately 90-95% of the diabetes market.
• Studies have shown that frequent blood glucose testing is not associated with improved glycemic control in type 2 diabetics and may result in decreased quality of life with higher levels of frustration, worries, and depression.
• Physicians would decrease or eliminate daily blood glucose testing for type 2 diabetics if monthly glycation monitoring, such as the G1A™ test, were available (Epinex survey of endocrinologists).
• Potential overall healthcare savings of $1 billion or more.

Screening For Pre-Diabetes and Metabolic Syndrome
G1A™ monthly testing would allow early detection of dangerous increases in glycation and enables lifestyle modification and prevention before the development of disease and its related complications.

• Has a market of as many as 54 million people in the U.S.
• Affects the overweight, elderly, and people with a family history of diabetes.
• Can decrease the prevalence of worldwide diabetes .

Coronary Artery Disease
Clinical studies in 2007 found “a strong and specific connection or association between elevated glycated albumin levels and coronary disease, with no correlation to HbA1c levels.”

• Approximately 9.8 million people in the US suffer chest pain due to narrowing of coronary arteries.
• Coronary heart disease is the single leading cause of death in America.
• G1A™ test could provide a useful marker for predicting the onset of coronary artery disease in people with type 2 diabetes.

Diabetes Drug Trials
The FDA has recommended that new drug therapies for type 2 diabetes provide evidence that therapy will not increase the risk of cardiovascular disease. The G1A™ test could be used as a cardiovascular disease marker during phase II and phase III clinical trials.